Skip to main content
Incyte Corporation
Healthcare · Biotechnology
Made on Aug 1, 2026
Price at call $119.52
6-month call Bear -5.0%
Target by Feb 2027 $113.50
Great value below $95.00
Model v0.6.0

Projection vs Actual (6M history + forecast)

The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change -5.0% to $113.50
Predicted High $121.50 at 1 month
Predicted Low $113.50 at 6 months
Max Drawdown (predicted) -5.0%

Forecast

The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded. Predicted Aug 1, 2026 12:59 am
Bear INCY trends lower to $113.50 (-5.0% from $119.52) by Feb 2027. ride-then-fade
ThesisINCY has momentum from a strong Q2 beat and EU Opzelura approval, but the composite fair value sits below current price. Expect near-term drift higher on sentiment tailwind, then gradual mean-reversion toward the $110-115 fair-value band as the catalyst fades and no new earnings print arrives until late in the window.
Invalidated ifA break above $130 on new pipeline data or below $105 on Jakafi erosion news would falsify this path.
Checkpointtime after the call Datewhen it gets graded Predictedthe claim: closing price Current priceactual close — fills in over time Predicted returnpredicted vs $119.52 at call Conv.brain's confidence, 1–10 Driverwhy the brain put the point here
Prediction made Aug 1, 2026 $119.52 at call The anchor — every point below is measured from this price and date.
2 weeks Aug 15, 2026 $110.47–$128.57 typical range · internal point $120.80 ±7.6% 7/10 Post-beat momentum and EU approval buzz persist
What actually happened: closed $120.17 on Aug 14, 2026 = +0.5% vs the call (predicted +1.1%)  ·  direction HIT (called flat, was flat)  ·  off by 0.5 pp  ·  accuracy 10/10  ·  typical range ±7.6%: inside the band  ·  S&P +4.0% over the same window — beat it
1 month Sep 1, 2026 $106.40–$132.64 typical range · internal point $121.50 ±11.0% 6/10 Low-beta drift higher in neutral tape
2 months Oct 1, 2026 $119.00 -0.4% 5/10 Catalyst fades, value gravity starts pulling
3 months Nov 1, 2026 $116.50 -2.5% 5/10 Convergence toward signal-adjusted fair value
4 months Dec 1, 2026 $115.00 -3.8% 5/10 No catalysts, mean-reversion continues quietly
5 months Jan 1, 2027 $114.00 -4.6% 4/10 Year-end tax positioning on winners
6 months Feb 1, 2027 $113.50 -5.0% 4/10 Settles near fair-value band pre-Q4 print

Why ranges on the short rungs? A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here — three prompt formulations all lost to simply predicting zero — while the stock's own volatility scale (σ×√t) described those windows well. So the short rungs claim what's actually knowable: the typical travel, with earnings timing flagged where the variance will come from. The internal point calls keep being generated and graded to map where real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.

Deterministic control (v0.3 value line) targets $117.45 (-1.7%) — both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it. Brain: claude-opus-4-7.

Weaknesses

0 blocking · 0 degraded · 1 note — follow the chain top-down (cause → effect).
  • Note
    Valuation anchor absent: dcf.
    anchor:dcf

Equation Inputs

Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.

Value anchors (from deep analysis)

Price at call$119.52
Composite fair value$99.53
Signal-adjusted fair value$116.05
DCF fair value
Anchored-PE fair value$160.22
Buy-below (value lens)$95.00
Value net score-46
Value confidence6 / 10
Quality net score+42
Memo confidence7 / 10
Deserved value (base)
Quality tilt
Deserved value (used)
Coherence (value × quality)

Price behaviour (trailing — shapes the realism line)

Realized volatility (annualized) 1m 40.0%  3m 38.0%  6m 35.0%  
Daily σ (realism noise)2.4%
Beta vs S&P 500 1m -0.15  3m -0.31  5m 0.30  
Trailing 6-month return18.2%

Knobs (equation params)

ladderArray
llm_modelclaude-opus-4-7
max_tokens3000
control_knobsArray
Neutral band (%)5
earnings_briefv1
prompt_versionp1
control_versionv0.3.0

Version & Tech Chain

What produced this prediction — stamped on the record so versions can be compared by success rate later.
Model v0.6.0 #271041f8fcd5

Tech composition (what this version is built from)

#ProcessKindGroup
1 Synthesis valuation-synthesis deterministic final
2 Scenario Analysis scenario-valuation deterministic valuation
3 Valuation / Mispricing ext-lens-value llm extended
4 Company Quality ext-lens-quality llm extended
5 Forensic Memo (combiner) ext-forensic-memo llm extended
6 Classification company-classification llm foundation
7 Live Quote fmp-quote data market-data

Inputs used (the runs that fed this prediction)

Upstream processRanLagRun id
company-classification Jul 30, 2026 freshest INCY-20260730-185629-e1b8
ext-forensic-memo Jul 30, 2026 freshest ext-INCY-20260730-191903-7908
ext-lens-quality Jul 30, 2026 freshest ext-INCY-20260730-191903-7908
ext-lens-sentiment Jul 30, 2026 freshest ext-INCY-20260730-191903-7908
ext-lens-value Jul 30, 2026 freshest ext-INCY-20260730-191903-7908
scenario-valuation Jul 30, 2026 freshest INCY-20260730-185629-e1b8
valuation-synthesis Jul 31, 2026 freshest INCY-20260730-185629-e1b8

Inputs flagged 7d+ behind the freshest one may be stale relative to the rest of the analysis.

Saved History

1 frozen snapshot — the record we score once predictions mature.
MadeModelCallAt callTargetExp.Eval due
Aug 1, 2026 v0.6.0 Bear $119.52 $113.50 -5.0% Feb 2027 viewing

Not Yet Modeled

What this v0.6.0 forecast deliberately ignores — the work ahead, in plain sight.
  • Scenario probabilities — one path, no bull/bear split (base_prob = 1.0).
  • Intraday / sub-2-week behaviour — the first claim is at 14 days by design (EOD product).
  • Position sizing / portfolio context — the path is a price claim only.